Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04553692
Title Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Solid Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors IGM Biosciences, Inc.
Indications

Advanced Solid Tumor

Therapies

Bevacizumab + Fluorouracil + IGM-8444 + Irinotecan + Leucovorin

Fluorouracil + IGM-8444 + Irinotecan + Leucovorin

IGM-8444

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Recruiting Duarte California 91010 United States Details
SCRI at Healthone Recruiting Denver Colorado 80218 United States Details
Yale Cancer Center Recruiting New Haven Connecticut 06510 United States Details
Florida Cancer Specialists Recruiting Sarasota Florida 34232 United States Details
Norton Cancer Institute Recruiting Louisville Kentucky 40241 United States Details
Stephenson Cancer Center Recruiting Oklahoma City Oklahoma 73104 United States Details
Providence Portland Medical Center Recruiting Portland Oregon 97213 United States Details
SCRI - Tennessee Recruiting Nashville Tennessee 37203 United States Details
Mary Crowley Cancer Research Recruiting Dallas Texas 75230 United States Details
The University of Texas, MD Anderson Recruiting Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field